Archive for January, 2009
In a new study, Cymbalta (duloxetine HCl) 60-120 mg, taken once daily, reduced pain severity significantly, compared with placebo, in patients with osteoarthritis pain of the knee. Data from the 13-week randomized, double-blind, placebo-controlled clinical trial(1) were presented at the annual meeting of the American Academy of Pain Medicine (AAPM) in Honolulu, Hawaii.
More: continued here
In a first-of-its-kind study published in the November 2008 Foot & Ankle International, the official journal of the American Orthopaedic Foot & Ankle Society (AOFAS), the expectation of orthopaedic post-operative pain was directly correlated with the actual incidence of pain following foot and ankle surgery. The lead author, AOFAS member Loretta B.
More: continued here
Journal of Clinical Oncology Summary of study being published online January 26, 2009 in the Journal of Clinical Oncology, showing no survival difference between premenopausal women with early-stage endometrial cancer whose ovaries were left intact during cancer surgery compared with those whose ovaries were surgically removed.
More: continued here
Old technologies, bone cement and a well known antibiotic, may effectively fight an emerging infection in soldiers with compound bone fractures, according to a study published online in the Journal of Orthopedic Research. An urgent search for solutions is underway as 20,000 additional American soldiers head for Afghanistan, and as evidence emerges that the infection studied may set the stage for more dangerous infections that can lead to amputation.
More: continued here
Astronauts spending months in space lose significant bone strength, making them increasingly at risk for fractures later in life. UC Irvine and UC San Francisco led a study evaluating 13 astronauts who spent four to six months on the International Space Station and found that, on average, astronauts’ hipbone strength decreased 14 percent. Three astronauts experienced losses of 20 percent to 30 percent, rates comparable to those seen in older women with osteoporosis.
More: continued here
DiFUSION Technologies, Inc., a medical device company targeting the orthopaedic market, has successfully completed a series of laboratory tests of its silver ion-based antimicrobial technology designed to mitigate Surgical Site Infections (SSIs) in spinal surgery. The technology will be incorporated into DiFUSION’s first spinal implant CleanFUZE(TM).
More: continued here
Artificial hip joints are firmly anchored to the patient’s damaged bone by screws. But which parts of the bone will safely hold the screws in place? A simulation model is to calculate the strength of the bone from computer tomography images. Hip prostheses do not hold forever. If an implant comes loose, the doctors have to replace it. Most patients need this second operation after about 15 years. By then, the first prosthesis has often worn down the pelvic bone in several places.
More: continued here
Biomedical engineers at The University of Texas Health Science Center at Houston are leading a multi-institution initiative to produce a bio-compatible compound designed to mend serious leg fractures. The researchers have been awarded $5.2 million in initial funding from the U.S. Department of Defense to develop “fracture putty” that could be used to regenerate bones shattered by roadside bombs or other explosive devices.
More: continued here
Medical News Today is pleased to announce the launch of a new Back Pain channel. The section will include news on the causes of back pain, including trapped nerves, spinal trauma, inflammatory disease and more. Plus information on treatments, surgery and clinical trials.
More: continued here
The American Association of Oral and Maxillofacial Surgeons has revised its 2006 landmark position paper on Bisphosphonate-Related Osteonecrosis of the Jaw to reflect the most current research and thought on this condition. BRONJ appears as a non-healing exposed bone in the maxillofacial region and may affect patients undergoing intravenous cancer-related bisphosphonate therapy or more rarely, patients treated with oral or IV bisphosphonates for osteoporosis.
More: continued here





